In conclusion, this is the first prospective phase III randomized trial to validate the benefit of switching to a non-cross-resistant regimen after NCT for non-responsive patients with HR + /HER2-/LN+ breast cancer. This evidence concerns the gene ERBB2 and breast cancer.